Co-occurrence of second primary malignancy in patients with thyroid cancer

QJM: An International Journal of Medicine

Volumn 107, Issue 8, 2014, Pages 643-648

  Hsu, C H ^a,b   Huang, C L ^a   Hsu, Y H ^a   Iqbal, U ^c   Nguyen, P A ^c   Jian, W S ^a  

^a TAIPEI MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER SURGERY; CENTRAL NERVOUS SYSTEM CANCER; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; FEMALE; GENETIC PREDISPOSITION; HEAD AND NECK CANCER; HEPATOBILIARY SYSTEM CANCER; HUMAN; KIDNEY CANCER; LARYNX CANCER; LEUKEMIA; LIVER CANCER; LUNG CANCER; LYMPHOID TISSUE CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MOUTH CANCER; MULTIMODALITY CANCER THERAPY; NASOPHARYNX CANCER; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; SALIVARY GLAND CANCER; SARCOMA; SECOND CANCER; SKIN CANCER; STOMACH CANCER; TAIWAN; THYROID CANCER; URETER CANCER; UTERINE CERVIX CANCER; ADOLESCENT; AGE DISTRIBUTION; FACTUAL DATABASE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDY; SEX RATIO; THYROID NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; DATABASES, FACTUAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; TAIWAN; THYROID NEOPLASMS; YOUNG ADULT;

EID: 84904874652     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcu051     Document Type: Article

References (34)

1. Rheingold SR, Neugut AI, Meadows AT. Secondary cancers: incidence, risk factors, and management. In: Bast RC, Jr, Kufe DW, Pollock RE, et al., eds, Holland-Frei Cancer Medicine, 5th edn, Chapter 156. Hamilton, ON: BC Decker INC, 2000.
2. Ronckers CM, McCarron P, Ron E. Thyroid cancer and multiple primary tumors in the SEER cancer registries. Int J Cancer. 2005; 117:281-8.
3. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, et al. Secondary primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007; 17:1277-88.
4. Sawka AM, Thabane L, Pariea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009; 19:451-7.
5. Kim C, Bi X, Pan D, Chen Y, Carling T, Ma S, et al. The risk of second cancer after diagnosis of primary thyroid cancer is elevated in thyroid microcarcinomas. Thyroid 2013; 23:575-82.
6. Iyer NG, Morris LGT, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who received radioactive iodine therapy. Cancer 2011; 117:4439-46.
7. Sarawagi S, Thomas S, Agrawal R. Integrating Association Rule Mining with Relational Database Systems: Alternatives and Implications. Data Min Knowl Discov 2000; 4:89-125.
8. Nguyen PA, Syed-Abdul S, Iqbal U, Hsu MH, Huang CL, Li HC, et al. A probabilistic model for reducing medication errors. PLoS ONE 2013; 8:e82401.
9. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006; 295:2164-7.
10. Chen AY, Jemal A, Ward EM. Increasing incidence of differentiated thyroid cancer in the United States, 1988-2005. Cancer 2009; 115:3801-7.
11. Vassiliadi DA, Tsagarakis S. Endocrine incidentaloma-challenges imposed by incidentally discovered lesions. Nat Rev Endocrinol 2011; 7:668-80.
12. Hay ID, McConahey WM, Goellner JR. Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000. Trans Am Clin Climatol Assoc 2002; 113:241-60.
13. Chen YK, Ding HJ, Chen KT, Chen YL, Liao AC, Shen YY, et al. Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for cancer screening in healthy subjects. Anticancer Res 2005; 25:1421-6.
14. Soelberg KK, Bonnema SJ, Brix TH, Hegedüs L. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid 2012; 92:918-25.
15. American Thyroid Association (ATA) Guidelines taskforce on thyroid nodules and differentiated thyroid cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19:1167-214.
16. 131I) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. Eur J Endocrinol 2005; 153:651-9.
17. Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B, et al. Strategies of radioiodine ablation in patients with low risk thyroid cancer. N Engl J Med 2012; 366:1663-73.
18. Detours V, Wattel S, Venet D, Hutsebaut N, Bogdanova T, Tronko MD, et al. Absence of a specific radiation signature in post-Chernobyl thyroid cancers. Br J Cancer 2005; 92:1545-52.
19. Dom G, Tarabichi M, Unger K, Thomas G, Oczko-Wojciechowska M, Bogdanova T, et al. A gene expression signature distinguishes normal tissues of sporadic and radiation-induced papillary thyroid carcinomas. Br J Cancer 2012; 107:994-1000.
20. Tucker MA, Jones PH, Boice JD, Jr, Robison LL, Stone BJ, Stovall M, et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res 1991; 51:2885-8.
21. Kogai T, Taki K, Brent GA. Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr Relat Cancer 2006; 13:797-826.
22. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R. The development of breast carcinoma in women with thyroid cancer. Cancer 2001; 92:225-31.
23. Van Fossen VL, Wilhelm SM, Eaton JL, Mc Henry CR. Association of thyroid, breast and renal cell cancer: a population-based study of the prevalence of second malignancies. Ann Surg Oncol 2013; 20:1341-7.
24. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA, Jr, Sigurdson AJ, et al. The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. J Clin Endocrinol Metab 2014; 99:E276-85.
25. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, et al. Detection of the PAX8-PPAR gamma fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2003; 88:354-7.
26. Nikiforova MN, Nikiforov YE. Molecular diagnostics and predictors in thyroid cancer. Thyroid 2009; 19:1351-61.
27. Xing M, Haugen BR, Schlumberger M. Progress in molecularbased management of differentiated thyroid cancer. Lancet 2013; 381:1058-69.
28. Bos JL. ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-9.
29. Mazzaferri FL, kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001; 86:1447-63.
30. Hercbergs AH, Ashur-Fabian O, Garfield D. Thyroid hormones and cancer: clinical studies of hypothyroidism in oncology. Curr Opin Endocrinol Diabetes Obes 2010; 17:432-6.
31. Hellevik AI, Asvold BO, Bjøro T, Romundstad PR, Nilsen TI, Vatten LJ. Thyroid function and cancer risk: a prospective population study. Cancer Epidemiol Biomarkers Prev 2009; 18:570-4.
32. Yeh NC, Chou CW, Weng SF, Yang CY, Yen FC, Lee SY, et al. Hyperthyroidism and thyroid cancer risk: a populationbased cohort study. Exp Clin Endocrinol Diabetes 2013; 121:402-6.
33. Chen YK, Lin CL, Chang YJ, Cheng TF, Peng CL, Sung FC, et al. Cancer risk in patients with Graves' disease: a nationwide cohort study. Thyroid 2013; 23:879-84.
34. Lu CH, Lee KD, Chen PT, Chen CC, Kuan FC, Huang CE, et al. Second primary malignancies following thyroid cancer: a population-based study in Taiwan. Eur J Endocrinol 2013; 169:577-85.